Eli Lilly and Company (LLY)vsPuma Biotechnology Inc (PBYI)
LLY
Eli Lilly and Company
$1,137.76
+1.98%
HEALTHCARE · Cap: $994.92B
PBYI
Puma Biotechnology Inc
$9.12
-0.55%
HEALTHCARE · Cap: $492.97M
Smart Verdict
WallStSmart Research — data-driven comparison
Eli Lilly and Company generates 34351% more annual revenue ($79.67B vs $231.24M). LLY leads profitability with a 33.5% profit margin vs 11.6%. PBYI appears more attractively valued with a PEG of 0.03. LLY earns a higher WallStSmart Score of 76/100 (B+).
LLY
Strong Buy76
out of 100
Grade: B+
PBYI
Strong Buy67
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for LLY.
Margin of Safety
+68.6%
Fair Value
$21.16
Current Price
$9.12
$12.04 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 79 in profit
Keeps 34 of every $100 in revenue as profit
Strong operational efficiency at 54.2%
Revenue surging 47.7% year-over-year
Earnings expanding 26.2% YoY
Growing faster than its price suggests
Conservative balance sheet, low leverage
Earnings expanding 35.8% YoY
Areas to Watch
Premium valuation, high expectations priced in
Elevated debt levels
Trading at 29.9x book value
Smaller company, higher risk/reward
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : LLY
The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 33.5% and operating margin at 54.2%. Revenue growth of 47.7% demonstrates continued momentum.
Bull Case : PBYI
The strongest argument for PBYI centers on PEG Ratio, Debt/Equity, EPS Growth. PEG of 0.03 suggests the stock is reasonably priced for its growth.
Bear Case : LLY
The primary concerns for LLY are P/E Ratio, Debt/Equity, Price/Book. Debt-to-equity of 1.62 is elevated, increasing financial risk.
Bear Case : PBYI
The primary concerns for PBYI are Market Cap, Altman Z-Score.
Key Dynamics to Monitor
LLY profiles as a growth stock while PBYI is a value play — different risk/reward profiles.
PBYI carries more volatility with a beta of 1.23 — expect wider price swings.
LLY is growing revenue faster at 47.7% — sustainability is the question.
LLY generates stronger free cash flow (7.8B), providing more financial flexibility.
Bottom Line
LLY scores higher overall (76/100 vs 67/100), backed by strong 33.5% margins and 47.7% revenue growth. PBYI offers better value entry with a 68.6% margin of safety. Both earn "Strong Buy" and "Strong Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Eli Lilly and Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Visit Website →Puma Biotechnology Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to improve cancer care in the United States and internationally. The company is headquartered in Los Angeles, California.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?